Melatonin for migraine prevention in children and adolescents: A randomized, double‐blind, placebo‐controlled trial after single‐blind placebo lead‐in
Headache: The Journal of Head and Face Pain · 2023
DOI: 10.1111/head.14600 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Amy A Gelfand und 8 weiteren Autor:innen. Beteiligte Einrichtung: Child & Adolescent Headache Program, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Melatonin, Migraine Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Weill Institute for Neurosciences, University of California, San Francisco.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Melatonin is effective for migraine prevention in adults. We hypothesized that melatonin would also be effective for migraine prevention in children and adolescents.
Methods
This was a randomized, double‐blind trial of melatonin (3 mg or 6 mg) versus placebo for migraine prevention in 10–17 year‐olds with 4–28/28 headache days at baseline. Participants were recruited from the UCSF Child & Adolescent Headache Program, UCSF child neurology clinic, and social media advertisements. Migraine diagnosis was confirmed by a headache specialist. Participants completed an 8‐week single‐blind placebo run‐in. Those meeting randomization criteria (≥4 headache days and ≥23/28 electronic diary entries during weeks 5–8) were randomized 1:1:1 to placebo:melatonin 3 mg:melatonin 6 mg nightly for 8 weeks. The primary outcome measure was migraine days in weeks 5–8 of randomized treatment between melatonin (combined 6 mg + 3 mg) versus placebo. We aimed to enroll n = 210.
Results
The study closed early due to slow enrollment ( n = 72). Two participants were in the single‐blind phase when the study closed, therefore the meaningful n = 70. Sixteen percent (11/70) were lost to follow‐up during the single‐blind phase. An additional 21% (15/70) did not meet randomization criteria (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Child & Adolescent Headache Program, University of California San Francisco, San Francisco, California, USA.
- Department of Neurology, University of California San Francisco, San Francisco, California, USA.
- Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California, USA.
- Minneapolis Clinic of Neurology, Minneapolis, Minnesota, USA.
- Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
ORCID-Profile: Amy A Gelfand, I Elaine Allen, Samantha Irwin
Förderung
- Weill Institute for Neurosciences, University of California, San Francisco
Zitieren
APA
Gelfand, A. A., Allen, I. E., Grimes, B., Irwin, S., Qubty, W., Greene, K., Waung, M., Powers, S. W., & Szperka, C. L. (2023). Melatonin for migraine prevention in children and adolescents: A randomized, double‐blind, placebo‐controlled trial after single‐blind placebo lead‐in. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14600
Vancouver
Gelfand AA, Allen IE, Grimes B, Irwin S, Qubty W, Greene K, et al. Melatonin for migraine prevention in children and adolescents: A randomized, double‐blind, placebo‐controlled trial after single‐blind placebo lead‐in. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14600
BibTeX
@article{Gelfand2023,
author = {Gelfand, Amy A and Allen, I Elaine and Grimes, Barbara and Irwin, Samantha and Qubty, William and Greene, Kaitlin and Waung, Maggie and Powers, Scott W and Szperka, Christina L},
title = {Melatonin for migraine prevention in children and adolescents: A randomized, double‐blind, placebo‐controlled trial after single‐blind placebo lead‐in},
journal = {Headache: The Journal of Head and Face Pain},
year = {2023},
doi = {10.1111/head.14600}
}
EUVIMED